Related Experiment Video
Updated: Jun 27, 2026
08:16
Noninvasive Monitoring of Lesion Size in a Heterologous Mouse Model of Endometriosis
Published on: February 26, 2019
Emerging drugs for endometriosis
1Shanghai Jiao Tong University School of Medicine, Renji Hospital, and Institute of Obstetric and Gynecologic Research, 145 Shandong Zhong Road, Shanghai 200001, China. hoxa10@gmail.com
Expert Opinion on Emerging Drugs
|December 3, 2008
Summary
Developing new endometriosis treatments faces challenges. Despite promising preclinical data, clinical trials show disappointing results, highlighting gaps in understanding pain and infertility mechanisms.
Area of Science:
- Reproductive Medicine
- Gynecology
- Pharmacology
Background:
- Endometriosis is a common gynecological disorder impacting women of reproductive age.
- It causes dysmenorrhea, pelvic pain, and subfertility.
- Current treatments are inadequate, necessitating novel therapeutic approaches.
Purpose of the Study:
- To review the development of new therapeutic agents for endometriosis.
- To assess preclinical and clinical findings for novel endometriosis treatments.
Main Methods:
- Comprehensive search of the PubMed database for compounds tested in endometriosis.
- Inclusion of both preclinical and clinical trial data.
Main Results:
- Several compound classes beyond traditional therapies have been investigated.
- Many completed Phase II/III trials lack published outcome data.
- Published Phase II trials yielded disappointing results, with some trials suspended.
Conclusions:
- A significant gap exists between preclinical promise and clinical outcomes for endometriosis therapies.
- Current understanding of endometriosis-associated pain, subfertility, and recurrence mechanisms is insufficient.
- Further research into endometriosis pathophysiology and improved animal models are crucial for therapeutic development.
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...